Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Transave |
---|---|
Information provided by: | Transave |
ClinicalTrials.gov Identifier: | NCT00558844 |
This is a study to determine the safety and tolerability of 28 days of daily dosing of 560 mg of Arikace™ versus placebo in patients who have Cystic fibrosis.
Condition | Intervention | Phase |
---|---|---|
Cystic Fibrosis |
Drug: Arikace™ |
Phase I Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Parallel Assignment, Safety/Efficacy Study |
Official Title: | Phase 1b/2a Multidose Safety and Tolerability Study of Liposomal Amikacin for Inhalation (Arikace™) in Cystic Fibrosis Patient With Chronic Infections Due to Pseudomonas Aeruginosa. |
Estimated Enrollment: | 40 |
Study Start Date: | June 2007 |
Estimated Study Completion Date: | April 2009 |
Estimated Primary Completion Date: | February 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
A: Active Comparator
Arikace at 560 mg
|
Drug: Arikace™
Subjects will be randomly assigned to study drug dose of of Arikace™ or placebo in accordance with a code provided by the Sponsor/CRO. Randomization will be made in a 2:1 allocation between Arikace™ and placebo. They will be blinded whether they receive Arikace™ or Placebo Study subjects will receive Arikace™ or placebo on Days 1 through Day 28. Drug is administered once a day via a nebulizer.
|
B: Placebo Comparator
Matching placebo
|
Drug: Arikace™
Subjects will be randomly assigned to study drug dose of of Arikace™ or placebo in accordance with a code provided by the Sponsor/CRO. Randomization will be made in a 2:1 allocation between Arikace™ and placebo. They will be blinded whether they receive Arikace™ or Placebo Study subjects will receive Arikace™ or placebo on Days 1 through Day 28. Drug is administered once a day via a nebulizer.
|
Cystic fibrosis (CF) is a gentic disease resulting from mutations in a 230 kb gene on chromosome 7 known as the cystic fibrosis transmembrane conductance regulator (CFTR). Study subjects with CF manifest pathological changes in a variety or organs that express CFTR. The lungs are frequently affected, the sequelae being chronic infections and airway inflammation. The principal goal of both treatment of subjects with CF is to slow the chronic deterioration of lung function.
Study subjects will be randomized to receive either study drug or placebo (1.5% NaCl) by inhalation via a PARI eFlow nebulizer. Each subject will complete 28 days of daily dosing. All study patients will be followed for safety, pharmacokinetics, clinical and microbiologic activity for 56 days post completion of study treatment. The total study period will be up to 84 days, with screening visit occurring within the preceding 14 days prior to study day 1. Patients will be clinically evaluated during the first 48 hours post first study dose and weekly for the 28 day treatment period and during the follow up visits at study days 35, 42, 49, 56, 70 and 85 days to determine safety and tolerability, pharmacokinetics (PK) and clinical and microbiologic activity.
Clinical laboratory parameters, audiology testing, clinical adverse events and pulmonary function will be evaluated for all study subjects in order to determine the qualitative and quantitative safety and tolerability of Arikace™ compared to placebo. Serum, urine and sputum specimens will be collected at periodic intervals to assess PK. Additionally, sputum samples will be collected to determine changes in bacterial density. Pulmonary function testing and CFQ-R measurements will be assessed at selected time points throughout the study. An exploratory evaluation of a Cystic Fibrosis Symptom Diary (CFSD) will also be implemented.
Ages Eligible for Study: | 6 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: J. P. Clancy, M.D. | 205-939-5479 | jclancy@peds.uab.edu |
United States, Alabama | |
University of Alabama | Recruiting |
Birmingham, Alabama, United States, 35233 | |
Contact: J.P. Clancy, M.D. 205-939-5479 jclancy@peds.uab.edu | |
Contact: Heather Young 205-939-9568 hyoung@peds.uab.edu |
Principal Investigator: | J. P. Clancy, M.D. | University of Alabama, 620 ACC, 1600 7th Avenue, South Birmingham, AL 35233 |
Responsible Party: | Transave ( Scott Rauscher, Clinical Project Manager ) |
Study ID Numbers: | TR02-106 |
Study First Received: | November 13, 2007 |
Last Updated: | October 14, 2008 |
ClinicalTrials.gov Identifier: | NCT00558844 |
Health Authority: | United States: Food and Drug Administration |
Cystic Fibrosis Respiratory Infections Pulmonary Cystic Fibrosis CFTR |
Digestive System Diseases Amikacin Genetic Diseases, Inborn Respiratory Tract Diseases Cystic Fibrosis Respiratory Tract Infections |
Fibrosis Lung Diseases Infant, Newborn, Diseases Pancreatic Diseases Cystic fibrosis |
Pathologic Processes |